Vicagrel
Vicagrel is the acetate form of the clopidogrel hydroxylated structure. It is now being developed as a thienopyridine antiplatelet agent. Contribution of CES2 and AADAC to vicagrel hydrolysis in 2-oxo-clopidogrel was 44.2 and 53.1% in human intestine, respectively. 2-oxo-clopidogrel is a substrate of hepatic CES1 giving the carboxylic acid form. 2-oxo-clopidogrel is a substrate of CYP450s giving the H4 active metabolite.
General
Type : Not A\/B H target, Drug, Pyridine, Acetate
Chemical_Nomenclature : methyl (2S)-2-(2-acetyloxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2-(2-chlorophenyl)acetate
Canonical SMILES : CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3Cl)C(=O)OC
InChI : InChI=1S\/C18H18ClNO4S\/c1-11(21)24-16-9-12-10-20(8-7-15(12)25-16)17(18(22)23-2)13-5-3-4-6-14(13)19\/h3-6,9,17H,7-8,10H2,1-2H3\/t17-\/m0\/s1
InChIKey : GNHHCBSBCDGWND-KRWDZBQOSA-N
Other name(s) : CHEMBL2042273 || SCHEMBL12438770 || ZINC84654546 || AJ-126334
MW : 379.85
Formula : C18H18ClNO4S
CAS_number :
PubChem : 53378151
UniChem : GNHHCBSBCDGWND-KRWDZBQOSA-N
Target
Structures : No structure
Families : Arylacetamide_deacetylase, Carb_B_Chordata
References (6)
| Title : Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic\/Pharmacodynamic Modeling Approach - Liu_2020_Front.Pharmacol_11_591854 |
| Author(s) : Liu S , Wang Z , Tian X , Cai W |
| Ref : Front Pharmacol , 11 :591854 , 2020 |
| Abstract : |
| PubMedSearch : Liu_2020_Front.Pharmacol_11_591854 |
| PubMedID: 33424602 |
| Title : Vicagrel enhances aspirin-induced inhibition of both platelet aggregation and thrombus formation in rodents due to its decreased metabolic inactivation - Jia_2019_Biomed.Pharmacother_115_108906 |
| Author(s) : Jia YM , Ge PX , Zhou H , Ji JZ , Tai T , Gu TT , Zhu T , Li YF , Mi QY , Huang BB , Xie HG |
| Ref : Biomed Pharmacother , 115 :108906 , 2019 |
| Abstract : |
| PubMedSearch : Jia_2019_Biomed.Pharmacother_115_108906 |
| PubMedID: 31060007 |
| Title : Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice - Jia_2018_J.Cardiovasc.Pharmacol_72_252 |
| Author(s) : Jia YM , Gu TT , Ji JZ , Tai T , Zhang MR , Huang BB , Zhou H , Mi QY , Xie HG |
| Ref : J Cardiovasc Pharmacol , 72 :252 , 2018 |
| Abstract : |
| PubMedSearch : Jia_2018_J.Cardiovasc.Pharmacol_72_252 |
| PubMedID: 30358688 |
| Title : Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans - Jiang_2017_Front.Pharmacol_8_846 |
| Author(s) : Jiang J , Chen X , Zhong D |
| Ref : Front Pharmacol , 8 :846 , 2017 |
| Abstract : |
| PubMedSearch : Jiang_2017_Front.Pharmacol_8_846 |
| PubMedID: 29209217 |
| Title : Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel - Qiu_2016_Front.Pharmacol_7_366 |
| Author(s) : Qiu ZX , Gao WC , Dai Y , Zhou SF , Zhao J , Lu Y , Chen XJ , Li N |
| Ref : Front Pharmacol , 7 :366 , 2016 |
| Abstract : |
| PubMedSearch : Qiu_2016_Front.Pharmacol_7_366 |
| PubMedID: 27774067 |
| Title : Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase - Shimizu_2014_Drug.Metab.Dispos_42_1103 |
| Author(s) : Shimizu M , Fukami T , Nakajima M , Yokoi T |
| Ref : Drug Metabolism & Disposition: The Biological Fate of Chemicals , 42 :1103 , 2014 |
| Abstract : |
| PubMedSearch : Shimizu_2014_Drug.Metab.Dispos_42_1103 |
| PubMedID: 24751575 |
| Gene_locus related to this paper: human-AADAC , human-CES1 , human-CES2 |